Saturday, July 11, 2026

pharma · Chronic Hepatitis B

Sun Yat-sen University

Third Affiliated Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Hepatitis B. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) t

CN HQ
3,680 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Employees
3,680
Programs
1
Drugs
2
Patents
0

Quick answer

Third Affiliated Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Hepatitis B. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: approved (1).

Company snapshot

Sun Yat-sen University, originally known as Guangdong University, was founded in 1924 by Dr. Sun Yat-sen (also called Sun Zhongshan), a great democratic revolutionary leader of the 20th century. The University is located in Guangdong Province, an area neighboring Hong Kong and Macao, which is at the forefront of China’s reform and opening up. Being one of the leading universities in the People’s R

  • 1 active pipeline program(s) linked via ClinicalTrials.gov.
  • 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Sun Yat-sen University. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum signals

Momentum

Proprietary activity score for Sun Yat-sen University.

1 active signal

7 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 1 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d
Competitive landscape
Recent activity

Recent activity

Latest pipeline, patent, and corporate events for Sun Yat-sen University.

  1. Clinical update

    Peginterferon alfa — Approved

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Sun Yat-sen University?

    Third Affiliated Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Hepatitis B. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and

  • Is Sun Yat-sen University publicly traded?

    Sun Yat-sen University appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Sun Yat-sen University develop or market?

    We link 2 drug profile(s) where Sun Yat-sen University is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/third-affiliated-hospital-sun-yat-sen-university#company-drugs.

  • What are the latest developments for Sun Yat-sen University?

    In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Sun Yat-sen University focus on?

    Sun Yat-sen University focuses on Chronic Hepatitis B based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Infectious Disease
2
Others
1